Pancreatic Cancer Research

ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Jun Gong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8713-1406; OpenAlex author ID A5101977319. Sources: ClinicalTrials.gov.

Their work

Papers
32 (first author 0, last author 3)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
79
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers, 1 trial · 2022: 7 papers · 2023: 4 papers · 2024: 4 papers · 2025: 4 papers · 2026: 2 papers, 1 trial

Papers 32

  1. Young Women With Pancreatic Cancer: A High-Risk Group for Demoralization. Co-author DOI 10.1002/pon.70601↗
  2. L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 Glut… Co-author DOI 10.1038/s43018-026-01225-z↗
  3. Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directed care. Co-author DOI 10.1016/j.hpb.2025.07.012↗
  4. Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. Co-author DOI 10.1093/oncolo/oyaf007↗
  5. Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. Co-author DOI 10.1200/po-24-00684↗
  6. Early Detection of Pancreatic Cancer: Current Advances and Future Opportunities. Co-author DOI 10.3390/biomedicines13071733↗
  7. Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation T… Co-author DOI 10.1016/j.adro.2024.101471↗
  8. Ascites Is a Poor Prognostic Factor in Advanced Pancreatic Adenocarcinoma and May Be Undertreated: A Prospective Cohort Study. Co-author DOI 10.14309/ctg.0000000000000719↗
  9. Fecal Microbiome Composition and Plasma Metabolomics in Pancreatic Cancer Cachexia Treated with Nutritional Support Last author DOI 10.20944/preprints202401.0727.v1↗
  10. The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analy… Co-author DOI 10.3390/cancers16050971↗
  11. Supraphysiological glutamine as a means of depleting intracellular amino acids to enhance pancreatic cancer chemosensitivity Co-author DOI 10.21203/rs.3.rs-3647514/v1↗
  12. Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol. Co-author DOI 10.3390/biomedicines11051392↗
  13. Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population-Based Study, 2000-2018. Co-author DOI 10.3390/cancers15030870↗
  14. Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer. Last author DOI 10.3390/cancers15113020↗
  15. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. Co-author DOI 10.1016/j.pan.2021.09.015↗
  16. Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-022-19401-3↗
  17. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-022-23619-6↗
  18. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. Co-author DOI 10.1053/j.gastro.2022.06.027↗
  19. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-3581↗
  20. Gut microbiome and pancreatic cancer cachexia: An evolving relationship. Last author DOI 10.4251/wjgo.v14.i7.1218↗
  21. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7039↗
  22. Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia. Co-author DOI 10.1002/jcsm.12799↗
  23. Advances in Pancreatic Ductal Adenocarcinoma Treatment. Co-author DOI 10.3390/cancers13215510↗
  24. Fecal elastase, an assay for exocrine pancreatic insufficiency, has clinical utility in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/1756284820964319↗
  25. Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib. Co-author DOI 10.1200/po.19.00365↗
  26. Priority Rankings of Patient-Reported Outcomes for Pancreatic Ductal Adenocarcinoma: A Comparison of Patient and Physician Perspectives. Co-author DOI 10.6004/jnccn.2020.7548↗
  27. Pancreatic cancer 'mismatch' in Lynch syndrome. Co-author DOI 10.1136/bmjgast-2019-000274↗
  28. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Co-author DOI 10.1186/s40169-018-0210-9↗
  29. Statins and pancreatic cancer. Co-author DOI 10.3892/ol.2017.5572↗
  30. Targeting mTOR in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2016.00099↗
  31. Meta-analyses of treatment standards for pancreatic cancer. Co-author DOI 10.3892/mco.2015.716↗
  32. Diabetes, pancreatic cancer, and metformin therapy. Co-author DOI 10.3389/fphys.2014.00426↗

Trials 2

  1. Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer Principal investigator NCT07864571↗
  2. Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer Principal investigator NCT04634539↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew Eugene Hendifar · 30 shared papers, 2016–2026 · strength 4.60
  2. Arsen Osipov · 20 shared papers, 2021–2026 · strength 3.51
  3. Stephen Jacob Pandol · 11 shared papers, 2014–2026 · strength 1.76
  4. Simon K. Lo · 9 shared papers, 2021–2026 · strength 1.50
  5. Srinivas Gaddam · 7 shared papers, 2022–2026 · strength 1.29
  6. Nicholas N. Nissen · 7 shared papers, 2021–2025 · strength 1.19
  7. Natalie Moshayedi · 7 shared papers, 2022–2024 · strength 1.09
  8. Neil A. Bhowmick · 6 shared papers, 2022–2026 · strength 1.05
  9. Hayato Muranaka · 6 shared papers, 2022–2026 · strength 1.05
  10. Veronica Placencio-Hickok · 7 shared papers, 2020–2024 · strength 1.04
  11. Abrahm Levi · 5 shared papers, 2023–2026 · strength 1.01
  12. Gillian K. Gresham · 5 shared papers, 2020–2025 · strength 0.70
  13. Matthew Ebia · 3 shared papers, 2025 · strength 0.64
  14. Brent K. Larson · 4 shared papers, 2019–2025 · strength 0.61
  15. Debiao Li · 3 shared papers, 2023–2025 · strength 0.59
  16. Michelle Guan · 4 shared papers, 2019–2022 · strength 0.50
  17. Michael Jon Pishvaian · 2 shared papers, 2025 · strength 0.46
  18. Yi Jiang · 2 shared papers, 2024–2025 · strength 0.44
  19. Alexandra Gangi · 2 shared papers, 2024–2025 · strength 0.39
  20. Mitchell R. Kamrava · 2 shared papers, 2024–2025 · strength 0.39
  21. Omer Hany Miligy Elmadbouh · 2 shared papers, 2023–2026 · strength 0.37
  22. Mouad Edderkaoui · 2 shared papers, 2023–2026 · strength 0.37
  23. Richard Tuli · 4 shared papers, 2016–2019 · strength 0.34
  24. Yazan Abboud · 2 shared papers, 2023–2024 · strength 0.34
  25. Emanuel F. Petricoin · 1 shared paper, 2025 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.